All In Biotech

NDA 022352 · Takeda Pharms USA

Colcrys

Colchicine · Oral

Priority reviewOrphanDiscontinued

Last checked: Nov 19, 2026Latest source record: May 14, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

Jul 29, 2009

Approved uses

1

Original approval plus efficacy supplements

Registered trials

313

94 Phase 3, 51 recruiting

FAERS reports

0

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 20, 2025.

1.1 Gout Flares Colchicine Tablets, USP are indicated for prophylaxis and the treatment of acute gout flares. Prophylaxis of Gout Flares: Colchicine Tablets, USP are indicated for prophylaxis of gout flares. Treatment of Gout Flares: Colchicine Tablets, USP are indicated for treatment of acute gout flares when taken at the first sign of a flare. 1.2 Familial Mediterranean Fever (FMF) Colchicine Tablets, USP are indicated in adults and children four years or older for treatment of familial Mediterranean fever (FMF).

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 29, 2009 Original approval · Type 7 - Drug Already Marketed without Approved NDA · priority review OrphanLabelReviewSummary Review
1 products under this application
  • COLCRYS · COLCHICINE 0.6MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Colchicine" as an intervention, any sponsor and status, largest first.

All 313 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Colcrys (Colchicine)

2024 spending

$236K

Beneficiaries

386

719 claims

Per beneficiary

$612

$6.61 per unit

View as table
YearSpending
2020$141,601,306
2021$10,099,833
2022$2,327,272
2023$1,044,075
2024$236,248

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 768 on PubMed

Sponsor: Takeda

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.